Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 20/20 | 0.62 |
| ▸ | CNR1 | P21554 | 4/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4467126 | 0.91 | CNR2 (0.61) | CNR2CNR1KCNH2 | |
| SCHEMBL5641965 | 0.89 | CNR2 (0.58) | CNR2CNR1KCNH2 | |
| SCHEMBL4467725 | 0.88 | CNR2 (0.58) | CNR2CNR1KCNH2 | |
| SCHEMBL3760023 | 0.86 | CNR2 (0.65) | CNR2KCNH2 | |
| SCHEMBL4474611 | 0.86 | CNR2 (0.57) | CNR2CNR1KCNH2 | |
| SCHEMBL13889151 | 0.85 | CNR2 (0.65) | CNR2CNR1 | |
| SCHEMBL4456616 | 0.85 | CNR2 (0.65) | CNR2CNR1 | |
| SCHEMBL3759637 | 0.83 | CNR2 (0.61) | CNR2CNR1KCNH2 | |
| SCHEMBL4467733 | 0.81 | CNR2 (0.59) | CNR2CNR1KCNH2 | |
| SCHEMBL4468620 | 0.81 | CNR2 (0.58) | CNR2CNR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070060583-A1 | Benzimidazole derivatives, compositions containing them, preparation therof and uses thereof | ASTRAZENECA AB (SE) | 2007-03-15 | — | — | US | claimed |
| JP-2006527247-A | — | — | 2006-11-30 | — | — | JP | claimed |
| EP-1636193-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | AstraZeneca AB (SE) | 2006-03-22 | — | — | EP | claimed |
| WO-2004108688-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | claimed |
| US-7517898-B2 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2009-04-14 | — | — | US | disclosed |
| US-7517898-B2 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2009-04-14 | — | — | US | disclosed |
| US-7517898-B2 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2009-04-14 | — | — | US | disclosed |
| US-20070060583-A1 | Benzimidazole derivatives, compositions containing them, preparation therof and uses thereof | ASTRAZENECA AB (SE) | 2007-03-15 | — | — | US | disclosed |
| US-20070060583-A1 | Benzimidazole derivatives, compositions containing them, preparation therof and uses thereof | ASTRAZENECA AB (SE) | 2007-03-15 | — | — | US | disclosed |
| US-20070060583-A1 | Benzimidazole derivatives, compositions containing them, preparation therof and uses thereof | ASTRAZENECA AB (SE) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060583-A1 | Benzimidazole derivatives, compositions containing them, preparation therof and uses thereof | BTF3, TYMS, F3 | CNR2 1312/4885CNR1 1207/4885KCNH2 990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.